In a trial presented by Dr Anders Pitzner-Fabricius (Rigshospitalet Copenhagen, Denmark), physically inactive adults with persistent asthma were randomised 2:1 to either a regimen of high-intensity interval training 3 times per week for 6 months (n=102), or to a control group of usual lifestyle (n=48) [1]. Both arms were followed up without intervention for an additional 6 months.
The results showed that the change in mean inhaled corticosteroid use (in micrograms) was reduced at 6 months in the high-intensity interval training arm by -234 micrograms (95% CI reduction -391 to -77; P=0.004), and even further by 12 months, even without intervention for the second 6-month period (-314 micrograms; 95% CI -477 to -151; P=0.002). When stratified by adherence to the high-intensity interval training regimen, the investigators reported that 71.4% of those with high adherence reduced their inhaled corticosteroid use by at least 25%, as opposed to 48.8% of the control group (P=0.09).
Dr Pitzner-Fabricius concluded that, in adults with asthma, high-intensity interval training exercise training has the potential to improve asthma control, reduce inhaled corticosteroid use, and has potential long-term positive lifestyle impact.
- Pitzner-Fabricius A, et al. The effects of high-intensity interval training on inhaled corticosteroids dose in patients with asthma – a randomized controlled trial. Session A16, ATS International Conference 2022, San Francisco, CA, USA, 13–18 May.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Obstructive sleep apnoea in most kids with PH Next Article
COVI-PRONE trial on its back »
« Obstructive sleep apnoea in most kids with PH Next Article
COVI-PRONE trial on its back »
Table of Contents: ATS 2022
Featured articles
No screening evidence for COPD
Online First
Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes?
Novel P2X3 antagonist can SOOTHE chronic cough
PAGANINI phase 2b data promising for eliapixant
POISE-3: Tranexamic acid for non-cardiac surgery
Colistimethate sodium PROMISing for non-cystic fibrosis bronchiectasis
Type 2 asthma managed by dupilumab, despite atopic comorbidities
NAVIGATOR steers asthma patients to tezepelumab
No screening evidence for COPD
High-intensity interval training slashes daily corticosteroids in asthma
Obstructive sleep apnoea in most kids with PH
Novel PDE4B inhibitor offers breakthrough for IPF
MANDALA patterns success for albuterol-budesonide in asthma
Lung transplantation after COVID-19-associated ARDS
Hydrocortisone does not help pre-term infants
CPAP supports pulmonary oxygenation in morbidly obese patients
Related Articles
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy